New Dual-Targeting CAR-T therapy shows promise for tough lymphoma
NCT ID NCT05421663
First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times
Summary
This study tests a new treatment called prizloncabtagene autoleucel (prizlo-cel) for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to other treatments. The therapy uses a patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The goal is to control the disease and improve response rates.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOLLICULAR LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Asan Medical Center
Seoul, 05505, South Korea
-
Calvary Mater Newcastle Hospital
Waratah, 2298, Australia
-
City of Hope
Duarte, California, 91010, United States
-
Colorado Blood Cancer Institute
Denver, Colorado, 80218, United States
-
Erasmus MC
Rotterdam, 3015 GD, Netherlands
-
Fiona Stanley Hospital
Murdoch, 6150, Australia
-
Greco Hainesworth Tennessee Oncology Centers for Research
Nashville, Tennessee, 37203, United States
-
Hosp Clinic de Barcelona
Barcelona, 08036, Spain
-
Hosp Univ Fund Jimenez Diaz
Madrid, 28040, Spain
-
Hosp Univ Vall D Hebron
Barcelona, 08035, Spain
-
ICO L'Hospitalet - Hospital Duran i Reynals
Barcelona, 08908, Spain
-
Levine Cancer Institute
Charlotte, North Carolina, 28001, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Odense University Hospital
Odense, 5000, Denmark
-
Princess Margaret Cancer Centre University Health Network
Toronto, Ontario, M5G2M9, Canada
-
Rigshospitalet
Copenhagen, 2100, Denmark
-
Rutgers Cancer Institute of New Jersey
Piscataway, New Jersey, 08854, United States
-
Samsung Medical Center
Seoul, 06351, South Korea
-
Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States
-
Seoul National University Hospital
Seoul, 03080, South Korea
-
St Vincents Hospital Melbourne
Fitzroy, 3065, Australia
-
St. David's South Austin Medical Center
Austin, Texas, 78704, United States
-
Swedish Cancer Institute
Seattle, Washington, 98104, United States
-
Texas Transplant Institute
San Antonio, Texas, 78229, United States
-
The Alfred Hospital
Melbourne, 3004, Australia
-
The Christie NHS Foundation Trust Christie Hospital
Manchester, M20 4BX, United Kingdom
-
UMC Utrecht
Utrecht, 3584 CX, Netherlands
-
University College London Hospitals
London, NW1 2BU, United Kingdom
-
University Hospitals Cleveland Medical Center
Cleveland, Ohio, 44106, United States
-
University of Iowa Hospital and Clinics
Iowa City, Iowa, 52242, United States
-
University of Kentucky Medical Center
Lexington, Kentucky, 40536, United States
-
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15232, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Rare childhood bone lymphoma: can past cases guide future care?
- Can a second CAR T-Cell infusion beat lymphoma that returns?
- New combo therapy aims to boost remission in Hard-to-Treat lymphoma
- Bispecific antibody shows promise for Hard-to-Treat lymphoma in Real-World study
- Engineered immune cells get a boost: new combo therapy targets Hard-to-Treat blood cancers
- New pill targets Hard-to-Treat lymphoma in early human test